Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Elsterwerda – page 58

1 019 clinical trials in Elsterwerda, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Elsterwerda at a glance
1 019
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 019 trials in Elsterwerda

Open in trial search

Study of Sotatercept for People with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Giant cell arteritis

Not recruiting

Study of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 706321
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Turning Point Therapeutics Inc.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Hypoparathyroidism

Not recruiting

Study on the Safety and Effectiveness of TransCon PTH for Adults with Hypoparathyroidism

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Palopegteriparatide
  • Sponsor:Ascendis Pharma Bone Diseases A/S

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Elsterwerda

What the registry says about research in the country

01 Metabolic Health Research

Clinical investigations focusing on weight management and Type 2 Diabetes treatments, evaluating innovative therapies for improved metabolic outcomes.

  • Weight reduction therapies
  • Diabetes management
  • Cardiovascular risk reduction

Studies combining lifestyle modifications with novel therapeutic approaches for comprehensive metabolic health improvement.

02 Cardiovascular Disease Studies

Research targeting atherosclerotic cardiovascular disease and innovative treatments for various forms of heart failure.

  • Atherosclerosis treatment
  • Heart failure management
  • Cardiac function improvement

Comprehensive evaluation of new therapeutic agents for both preserved and reduced ejection fraction heart failure.

03 Circulatory System Disorders

Advanced clinical research examining treatments for resistant hypertension and atrial fibrillation, focusing on innovative therapeutic approaches.

  • Blood pressure management
  • Stroke prevention
  • Cardiac rhythm disorders

Evaluating next-generation medications for better control of complex cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.